WO2018085198A1 - 5-halouracil-modified micrornas and their use in the treatment of cancer - Google Patents

5-halouracil-modified micrornas and their use in the treatment of cancer Download PDF

Info

Publication number
WO2018085198A1
WO2018085198A1 PCT/US2017/059011 US2017059011W WO2018085198A1 WO 2018085198 A1 WO2018085198 A1 WO 2018085198A1 US 2017059011 W US2017059011 W US 2017059011W WO 2018085198 A1 WO2018085198 A1 WO 2018085198A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
modified
nucleic acid
halouracil
cancer
Prior art date
Application number
PCT/US2017/059011
Other languages
English (en)
French (fr)
Inventor
Jingfang Ju
Original Assignee
The Research Foundation For The State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP17867742.3A priority Critical patent/EP3534912A4/en
Application filed by The Research Foundation For The State University Of New York filed Critical The Research Foundation For The State University Of New York
Priority to KR1020197015788A priority patent/KR102502248B1/ko
Priority to BR112019008810A priority patent/BR112019008810A2/pt
Priority to CA3042401A priority patent/CA3042401A1/en
Priority to CN201780081456.7A priority patent/CN110290794A/zh
Priority to JP2019523008A priority patent/JP7130639B2/ja
Priority to MX2019005101A priority patent/MX2019005101A/es
Priority to AU2017353907A priority patent/AU2017353907B2/en
Publication of WO2018085198A1 publication Critical patent/WO2018085198A1/en
Priority to US16/176,137 priority patent/US11584932B2/en
Priority to US16/912,932 priority patent/US11236337B2/en
Priority to JP2022133279A priority patent/JP2022173194A/ja
Priority to US18/159,233 priority patent/US20230365972A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2017/059011 2016-11-01 2017-10-30 5-halouracil-modified micrornas and their use in the treatment of cancer WO2018085198A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2019523008A JP7130639B2 (ja) 2016-11-01 2017-10-30 ５－ハロウラシル修飾マイクロｒｎａ及びがんの処置におけるその使用
KR1020197015788A KR102502248B1 (ko) 2016-11-01 2017-10-30 5-할로우라실-변형 마이크로rna 및 암 치료시 그 용도
BR112019008810A BR112019008810A2 (pt) 2016-11-01 2017-10-30 micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
CA3042401A CA3042401A1 (en) 2016-11-01 2017-10-30 5-halouracil-modified micrornas and their use in the treatment of cancer
CN201780081456.7A CN110290794A (zh) 2016-11-01 2017-10-30 5-卤代尿嘧啶修饰的微rna及其在癌症治疗中的用途
EP17867742.3A EP3534912A4 (en) 2016-11-01 2017-10-30 5-HALOURACIL-MODIFIED MICRORNAS AND THEIR USES IN THE TREATMENT OF CANCER
MX2019005101A MX2019005101A (es) 2016-11-01 2017-10-30 Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
AU2017353907A AU2017353907B2 (en) 2016-11-01 2017-10-30 5-halouracil-modified microRNAs and their use in the treatment of cancer
US16/176,137 US11584932B2 (en) 2016-11-01 2018-10-31 5-halouracil-modified microRNAs and their use in the treatment of cancer
US16/912,932 US11236337B2 (en) 2016-11-01 2020-06-26 5-halouracil-modified microRNAs and their use in the treatment of cancer
JP2022133279A JP2022173194A (ja) 2016-11-01 2022-08-24 ５－ハロウラシル修飾マイクロｒｎａ及びがんの処置におけるその使用
US18/159,233 US20230365972A1 (en) 2016-11-01 2023-01-25 5-halouracil-modified micrornas and their use in the treatment of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662415740P 2016-11-01 2016-11-01
US62/415,740 2016-11-01
US201662422298P 2016-11-15 2016-11-15
US62/422,298 2016-11-15
US201762464491P 2017-02-28 2017-02-28
US62/464,491 2017-02-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/176,137 Continuation-In-Part US11584932B2 (en) 2016-11-01 2018-10-31 5-halouracil-modified microRNAs and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
WO2018085198A1 true WO2018085198A1 (en) 2018-05-11

Family

ID=62077036

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2017/059011 WO2018085198A1 (en) 2016-11-01 2017-10-30 5-halouracil-modified micrornas and their use in the treatment of cancer
PCT/US2019/058706 WO2020092466A1 (en) 2016-11-01 2019-10-30 5-halouracil-modified micrornas and their use in the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2019/058706 WO2020092466A1 (en) 2016-11-01 2019-10-30 5-halouracil-modified micrornas and their use in the treatment of cancer

Country Status (12)

Country Link
US (2) US11584932B2 (zh)
EP (2) EP3534912A4 (zh)
JP (2) JP7130639B2 (zh)
KR (2) KR102502248B1 (zh)
CN (2) CN110290794A (zh)
AU (2) AU2017353907B2 (zh)
BR (1) BR112019008810A2 (zh)
CA (1) CA3042401A1 (zh)
IL (1) IL282836A (zh)
MX (1) MX2019005101A (zh)
SG (1) SG11202104571RA (zh)
WO (2) WO2018085198A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092466A1 (en) * 2016-11-01 2020-05-07 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP3937980A4 (en) * 2019-03-14 2023-08-02 The Research Foundation for The State University of New York MODIFIED MIARNS AND THEIR USE IN THE TREATMENT OF CANCER

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110527728A (zh) * 2013-08-08 2019-12-03 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白
US10941403B2 (en) 2018-04-02 2021-03-09 Oregon Health & Science University Microrna inhibitors as anti-cancer therapeutics
MX2022011515A (es) * 2020-03-18 2022-10-07 Univ New York State Res Found Composiciones de arn modificado de interferencia corta y su uso en el tratamiento del cancer.
WO2021262919A2 (en) * 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261218A1 (en) * 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US20110166201A1 (en) * 2008-06-05 2011-07-07 Jingfang Ju Mirnas as therapeutic targets in cancer
US20120087992A1 (en) * 2009-03-20 2012-04-12 Jingfang Ju miRNAS AS THERAPEUTIC TARGETS IN CANCER
US20120202981A1 (en) * 2009-06-29 2012-08-09 Aptabio Therapeutics Inc. Novel guanosine-rich modified oligonucleotides and antiproliferative activity thereof
US20130109628A1 (en) * 2010-07-15 2013-05-02 Emory University Microrna compositions and methods related thereto

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
CA2937159C (en) * 2001-09-28 2017-11-28 Thomas Tuschl Microrna molecules
US20050261217A1 (en) 2004-05-18 2005-11-24 Isis Pharmaceuticals Inc. Modulation of pumilio 1 expression
US7642348B2 (en) 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US20070259349A1 (en) 2006-05-04 2007-11-08 Itzhak Bentwich Bladder cancer-related nucleic acids
US7592441B2 (en) 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
CA2850323A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
JP2008539731A (ja) 2005-05-02 2008-11-20 コールド スプリング ハーバー ラボラトリー 癌の診断及び治療のための組成物及び方法
CA2610702A1 (en) 2005-06-03 2006-12-07 Michael Zenon Michael Targeting cells with altered microrna expression
US20090209621A1 (en) 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
CN103866017B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
ES2523989T3 (es) * 2005-09-12 2014-12-03 The Ohio State University Research Foundation Composiciones para la terapia de cánceres asociados con BCL2
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2007205257B2 (en) 2006-01-05 2013-07-25 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
EP2487253B1 (en) 2006-01-05 2015-06-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007103808A2 (en) 2006-03-02 2007-09-13 The Ohio State University Microrna expression profile associated with pancreatic cancer
EP1996731A2 (en) 2006-03-20 2008-12-03 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EA201100813A1 (ru) 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
US20080076674A1 (en) 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
ES2447850T3 (es) 2006-07-13 2014-03-13 The Ohio State University Research Foundation Métodos y composiciones basados en micro-ARN para el pronóstico y tratamiento de enfermedades relacionadas con el colon
US8466117B2 (en) 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis
JP2010504350A (ja) 2006-09-19 2010-02-12 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−２００によって調節される遺伝子および経路
WO2008036718A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-143 regulated genes and pathways as targets for therapeutic intervention
WO2008046911A2 (en) 2006-10-20 2008-04-24 Exiqon A/S Novel human micrornas associated with cancer
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
EP2113567B1 (en) 2006-12-21 2019-04-03 QIAGEN GmbH MicroRNA target site blocking oligos and uses thereof
EP2124967A4 (en) 2007-01-26 2011-01-05 Rosetta Genomics Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEMATOPOIETIC MALIGNOMES
WO2008095096A2 (en) 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
WO2008137862A2 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Methods of using mir34 as a biomarker for tp53 functional status
CN101802227B (zh) * 2007-07-18 2014-12-10 科罗拉多大学董事会法人团体 非衰竭与衰竭的人心脏中微小rna的差异表达
EP3138926A3 (en) 2007-09-06 2017-04-05 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
BRPI0816852A2 (pt) 2007-09-14 2017-06-06 Univ Ohio State Res Found método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.
US8361714B2 (en) * 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090136957A1 (en) 2007-09-15 2009-05-28 Irena Ivanovska Methods and compositions for regulating cell cycle progression via the miR-106B family
US20100285471A1 (en) 2007-10-11 2010-11-11 The Ohio State University Research Foundation Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas
AU2008318778B2 (en) 2007-10-29 2014-10-02 Regulus Therapeutics Inc. Targeting microRNAs for the treatment of liver cancer
US20110009469A1 (en) 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
JP2011517283A (ja) 2008-02-28 2011-06-02 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 前立腺関連障害の予後診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
US8252760B2 (en) 2008-03-24 2012-08-28 New York University Compositions and methods for diagnosing and treating melanoma
WO2009154835A2 (en) 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
US20100113284A1 (en) 2008-04-04 2010-05-06 Alexander Aristarkhov Small interfering rna (sirna) target site blocking oligos and uses thereof
US20090258928A1 (en) 2008-04-08 2009-10-15 Asuragen, Inc. Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US20110166200A1 (en) 2008-04-24 2011-07-07 Zhan Zhang Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
ATE550024T1 (de) 2008-05-30 2012-04-15 Univ Yale Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression
WO2009147658A2 (en) 2008-06-02 2009-12-10 New York University Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
US9540695B2 (en) 2008-06-17 2017-01-10 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
US20110118337A1 (en) 2008-07-10 2011-05-19 Merck Sharp & Dohme Corp. Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
WO2010023658A2 (en) 2008-08-28 2010-03-04 Rosetta Genomics Ltd. Compositions and methods for the treatment of glioblastoma
ES2727549T3 (es) 2008-10-03 2019-10-17 Curna Inc Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1
WO2010065630A2 (en) 2008-12-03 2010-06-10 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
JP5971948B2 (ja) 2008-12-04 2016-08-17 クルナ・インコーポレーテッド Ｖｅｇｆに対する天然アンチセンス転写物の抑制による血管内皮増殖因子（ｖｅｇｆ）関連疾患の治療
CA2745811C (en) 2008-12-04 2021-07-13 Joseph Collard Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
ES2760912T3 (es) 2008-12-04 2020-05-18 Curna Inc Tratamiento de enfermedades relacionadas con la Sirtuina 1 (SIRT1) por inhibición del transcrito antisentido natural de la Sirtuina 1
AU2009322907B2 (en) 2008-12-05 2016-05-05 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
US20100311815A1 (en) 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
WO2010099342A2 (en) * 2009-02-25 2010-09-02 Cepheid Methods of detecting lung cancer
EP2403946A4 (en) 2009-03-04 2012-11-14 TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1
WO2010104796A2 (en) 2009-03-09 2010-09-16 The J. David Gladstone Institutes Methods of modulating smooth muscle cell proliferation and differentiation
US8852940B2 (en) * 2009-04-01 2014-10-07 The Regents Of The University Of California Embryonic stem cell specific microRNAs promote induced pluripotency
KR101758667B1 (ko) * 2009-04-29 2017-07-18 아카데미쉬 메디쉬 센트륨 심부전 또는 심부전 위험성을 방지, 예방 및/또는 측정하기 위한 수단 및 방법
NO2424987T3 (zh) 2009-05-01 2018-04-14
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
WO2011014980A1 (en) 2009-08-07 2011-02-10 Capitalbio Corporation Methods and compositions diagnosing cervical cancer and cervical dysplasia, guidding subsequent treatment, determining prognosis, and improving patient survival
US8822144B2 (en) 2009-08-19 2014-09-02 Rosetta Genomics Ltd. Compositions and methods for prognosis and treatment of prostate cancer
WO2011024157A1 (en) 2009-08-23 2011-03-03 Rosetta Genomics Ltd. Nucleic acid sequences related to cancer
WO2011030334A1 (en) 2009-09-09 2011-03-17 New York University Compositions and methods for treatment, diagnosis and prognosis of mesothelioma
EP2496714B1 (en) * 2009-11-04 2016-08-31 DiamiR, LLC Methods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment
EP2513310B1 (en) 2009-12-16 2017-11-01 CuRNA, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
CA2785177C (en) 2009-12-29 2019-09-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
CN102906264B (zh) 2010-01-04 2017-08-04 库尔纳公司 通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
US8946182B2 (en) 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
KR101838308B1 (ko) 2010-02-22 2018-03-13 큐알엔에이, 인크. 피롤린-5-카르복실레이트 환원효소 1(ｐｙｃｒ1)에 대한 천연 안티센스 전사체의 억제에 의한 ｐｙｃｒ1과 관련된 질환의 치료
WO2011108930A1 (en) * 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
WO2011113030A2 (en) 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Human cancer micro-rna expression profiles predictive of chemo-response
WO2011116152A2 (en) 2010-03-16 2011-09-22 Sanford -Burnham Medical Research Institute Delivery of agents using interfering nanoparticles
CA2795281A1 (en) 2010-04-09 2011-10-13 Curna, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
US20130131148A1 (en) 2010-04-12 2013-05-23 Noam Shomron Micro-rna for cancer diagnosis, prognosis and therapy
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
AR081209A1 (es) 2010-05-19 2012-07-04 Opko Curna Llc Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11
NO2576783T3 (zh) 2010-05-26 2018-04-28
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
WO2012009347A2 (en) 2010-07-12 2012-01-19 Opko Curna Llc Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
CN103180461A (zh) 2010-07-25 2013-06-26 纽约大学 用于间皮瘤预后的组合物和方法
EP2598657B1 (en) 2010-08-01 2016-10-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Microrna patterns for the diagnosis, prognosis and treatment of melanoma
EP2625274B1 (en) 2010-10-06 2017-07-19 CuRNA, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
KR101343616B1 (ko) 2010-10-08 2013-12-20 연세대학교 산학협력단 췌장암 치료용 약제학적 조성물 및 췌장암 치료제 스크리닝 방법
JP6336755B2 (ja) 2010-11-12 2018-06-06 ザ ジェネラル ホスピタル コーポレイション ポリコームに関連する非コードｒｎａ
US20140045924A1 (en) 2010-12-15 2014-02-13 Medimmune, Llc Melanoma treatments
AU2011352036A1 (en) * 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US8883757B2 (en) 2011-01-03 2014-11-11 Rosetta Genomics Ltd. Compositions and methods for treatment of ovarian cancer
EP2474617A1 (en) * 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
AU2012212105A1 (en) * 2011-02-03 2013-09-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-124
US9132152B2 (en) 2011-02-10 2015-09-15 The Regents Of The University Of California Compositions and methods for generating induced pluripotent stem cells
CA2830301A1 (en) 2011-03-18 2012-09-27 Baylor Research Institute Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis
US8987224B2 (en) * 2011-08-05 2015-03-24 Baylor College Of Medicine MicroRNA-198 as a tumor suppressor in pancreatic cancer
WO2013056216A1 (en) * 2011-10-14 2013-04-18 New York University Micrornas and methods of using same
CN104080461A (zh) 2011-11-30 2014-10-01 雪松-西奈医学中心 靶向微小rna mir-409-5p、mir-379和mir-154*来治疗前列腺癌骨转移和耐药性肺癌
US9745578B2 (en) 2011-11-30 2017-08-29 Cedars-Sinai Medical Center Targeting microRNA miR-409-3P to treat prostate cancer
US20140363469A1 (en) * 2012-01-19 2014-12-11 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
HUE040179T2 (hu) 2012-03-15 2019-02-28 Curna Inc Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
EP2838541A1 (en) * 2012-04-20 2015-02-25 Agency For Science, Technology And Research Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
US10059941B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
AU2013262699A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating ATP2A2 expression
EA201492119A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии apoa1 и abca1
CN104602714A (zh) 2012-05-16 2015-05-06 Rana医疗有限公司 用于调节bdnf表达的组合物和方法
EP2850188A4 (en) 2012-05-16 2016-01-20 Rana Therapeutics Inc COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE MULTIGENIC FAMILY OF HEMOGLOBIN
EP3511416A1 (en) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Compositions and methods for modulating gene expression
US20150159161A1 (en) 2012-05-16 2015-06-11 Rana Therapeutics, Inc. Compositions and methods for modulating pten expression
CN104583402A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
WO2014011975A2 (en) 2012-07-12 2014-01-16 Baylor College Of Medicine Micrornas sensitize cancers to therapy
US9096853B2 (en) * 2012-09-24 2015-08-04 U.S. Department Of Veterans Affairs Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity
ES2782825T3 (es) 2012-10-31 2020-09-16 Univ Rockefeller Tratamiento de cáncer de colon metastásico
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
US9416369B2 (en) * 2012-12-18 2016-08-16 University Of Washington Through Its Center For Commercialization Methods and compositions to modulate RNA processing
US10697020B2 (en) * 2013-05-15 2020-06-30 The Research Foundation For The State University Of New York MicroRNA-129 as a biomarker for colorectal cancer
EP3004354A4 (en) 2013-06-07 2017-01-11 Rana Therapeutics, Inc. Compositions and methods for modulating foxp3 expression
US20150151004A1 (en) * 2013-06-14 2015-06-04 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
AU2014342535B2 (en) * 2013-10-28 2020-04-02 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
US20160312301A1 (en) 2013-12-20 2016-10-27 The Feinstein Institute For Medical Research Microrna biomarkers for ovarian cancer
JP2017511694A (ja) 2014-02-12 2017-04-27 トーマス・ジェファーソン・ユニバーシティ マイクロｒｎａ阻害剤を使用するための組成物および方法
KR101596166B1 (ko) 2014-10-07 2016-02-19 가톨릭대학교 산학협력단 유방암 진단 및 치료를 위한 마이크로 ｒｎａ의 용도
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
EP3331546B1 (en) 2015-08-03 2023-10-04 Biokine Therapeutics Ltd. Cxcr4 inhibitor for the treatment of cancer
US10053696B2 (en) 2016-01-21 2018-08-21 University Of South Carolina MiRNA-489 in treatment of breast cancer
CA3042401A1 (en) 2016-11-01 2018-05-11 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
US10988766B2 (en) 2017-01-06 2021-04-27 Oregon Health & Science University Compositions and methods used in diagnosing and treating colorectal cancer
WO2018136919A2 (en) 2017-01-23 2018-07-26 Trustees Of Boston University Methods relating to lung cancer
KR101953300B1 (ko) 2018-06-22 2019-02-28 의료법인 성광의료재단 탁산계 항암제 내성 암의 진단 및 치료를 위한 조성물, 키트 및 방법
MA53669A (fr) 2018-09-20 2021-07-28 Modernatx Inc Compositions et procédés d'administration d'acides nucléiques
AU2019381681A1 (en) 2018-11-13 2021-05-27 Regulus Therapeutics Inc. Microrna compounds and methods for modulating miR-10b activity
WO2020154207A1 (en) 2019-01-22 2020-07-30 Research Institute At Nationwide Children's Hospital A novel method for monitoring and treating oral cancer
US20220145304A1 (en) 2019-03-14 2022-05-12 The Research Foundation For The State University Of New York Modified micrornas and their use in the treatment of cancer
US20220275374A1 (en) 2019-11-14 2022-09-01 The Board Of Regents Of The University Of Oklahoma Oligonucleotide interference treatments of prostate cancer
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261218A1 (en) * 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US20110166201A1 (en) * 2008-06-05 2011-07-07 Jingfang Ju Mirnas as therapeutic targets in cancer
US20120087992A1 (en) * 2009-03-20 2012-04-12 Jingfang Ju miRNAS AS THERAPEUTIC TARGETS IN CANCER
US20120202981A1 (en) * 2009-06-29 2012-08-09 Aptabio Therapeutics Inc. Novel guanosine-rich modified oligonucleotides and antiproliferative activity thereof
US20130109628A1 (en) * 2010-07-15 2013-05-02 Emory University Microrna compositions and methods related thereto

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IWAIZUMI ET AL.: "DNA Mismatch Repair Proficiency executing 5-Fluorouracil Cytotoxicity in Colorectal Cancer Cells", CANCER BIOLOGY & THERAPY, vol. 12, 15 October 2011 (2011-10-15), pages 756 - 764, XP055482654, Retrieved from the Internet <URL:doi:10.4161/cbt.12.8.17169> *
KARAAYVAZ ET AL.: "miR-129 Promotes Apoptosis and Enhances Chemosensitivity to 5-Fluorouracil in Colorectal Cancer", CELL DEATH & DISEASE, vol. 4, no. 6, 1 June 2013 (2013-06-01), pages e659, XP055482657, Retrieved from the Internet <URL:doi:10.1038/cddis.2013.193.> *
PETTERSEN ET AL.: "UNG-Initiated Base Excision Repair is the Major Repair Route for 5-Fluorouracil in DNA, but 5-Fluorouracil Cytotoxicity Depends Mainly on RNA Incorporation", NUCLEIC ACIDS RESEARCH, vol. 39, no. 19, 10 July 2011 (2011-07-10), pages 8430 - 8444, XP055482660, Retrieved from the Internet <URL:doi:10.1093/nar/gkr563> *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092466A1 (en) * 2016-11-01 2020-05-07 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP3937980A4 (en) * 2019-03-14 2023-08-02 The Research Foundation for The State University of New York MODIFIED MIARNS AND THEIR USE IN THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
IL282836A (en) 2021-06-30
KR102502248B1 (ko) 2023-02-21
US20230365972A1 (en) 2023-11-16
US11584932B2 (en) 2023-02-21
US20190062754A1 (en) 2019-02-28
EP3534912A1 (en) 2019-09-11
AU2017353907A1 (en) 2019-05-23
EP3534912A4 (en) 2020-10-07
JP2019533697A (ja) 2019-11-21
KR20190086688A (ko) 2019-07-23
CN110290794A (zh) 2019-09-27
SG11202104571RA (en) 2021-06-29
JP2022173194A (ja) 2022-11-18
CN113573781A (zh) 2021-10-29
JP7130639B2 (ja) 2022-09-05
AU2017353907B2 (en) 2023-11-30
CA3042401A1 (en) 2018-05-11
WO2020092466A1 (en) 2020-05-07
KR20210088614A (ko) 2021-07-14
EP3873613A1 (en) 2021-09-08
EP3873613A4 (en) 2023-11-15
AU2019371830A1 (en) 2021-06-03
BR112019008810A2 (pt) 2019-07-16
MX2019005101A (es) 2019-08-22

Similar Documents

Publication Publication Date Title
AU2017353907B2 (en) 5-halouracil-modified microRNAs and their use in the treatment of cancer
JP2018507866A (ja) マイクロｒｎａを有効成分として含む癌治療用医薬組成物
US20220145304A1 (en) Modified micrornas and their use in the treatment of cancer
JP2021513508A (ja) 抗がんマイクロｒｎａ及びその脂質製剤
US11236337B2 (en) 5-halouracil-modified microRNAs and their use in the treatment of cancer
TWI526211B (zh) RNAi molecules for thymidine nucleotide synthesis enzymes and their use
US20220090076A1 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
US10697020B2 (en) MicroRNA-129 as a biomarker for colorectal cancer
US20230151363A1 (en) Modified short-interfering rna compositions and their use in the treatment of cancer
WO2015072247A1 (ja) がん幹細胞標的薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17867742

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019523008

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3042401

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019008810

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017353907

Country of ref document: AU

Date of ref document: 20171030

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197015788

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017867742

Country of ref document: EP

Effective date: 20190603

ENP Entry into the national phase

Ref document number: 112019008810

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190430